Found 67 results
Author Title Type [ Year(Desc)]
Filters: Author is Van Veldhuisen, P  [Clear All Filters]
1998
J. B. Copley, Staffeld, C., Lindberg, J., Hansen, A., Bailey, C., Anand, R., and Van Veldhuisen, P., “Cyclosporine to tacrolimus: effect on hypertension and lipid profiles in renal allografts.”, Transplant Proc, vol. 30, no. 4, pp. 1254-6, 1998.
1999
T. Gonwa, Ahsan, N., Halloran, P., Stegal, M., Hardy, M., Metzgar, R., Shield, III, C., Rocher, L., Scandling, J., Sorensen, L., Mulloy, L., Light, J., Corwin, C., Danovitch, G., Wachs, M., Van Veldhuisen, P., Salm, K., Tolzman, D., and Fitzsimmons, W., “Comparative trial of Prograf™ (tacrolimus) in combination with azathiprine or mycophenolate mofetil vs. neoral (cyclosporine) with mycophenolate mofeitil after kidney transplantation”, 1999.
J. Copley, Staffeld, C., Lindberg, J., Baily, C., and Van Veldhuisen, P., “The conversion of kidney transplant patients to tacrolimus from cyclosporine because of refractory rejection or significant cyclosporine toxicity”, 1999.
C. O. Taylor, Barr, M. L., Radovancevic, B., Renlund, D. G., Mentzer, Jr., R. M., Smart, F. W., Tolman, D. E., Frazier, O. H., Young, J. B., and Van Veldhuisen, P., “A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardia transplantation: decreased hyperlipidemia and hypertension with tacrolimus”, J Heart Lung Transplant, vol. 18, pp. 336-345, 1999.
R. B. Nussenblatt, Fortin, E., Schiffman, R., Rizzo, L., Smith, J., Van Veldhuisen, P., Sran, P., Yaffe, A., Goldman, C. K., Waldmann, T. A., and Whitcup, S. M., “Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial”, Proceedings of the National Academy of Science USA, vol. 96, pp. 7462-66, 1999.
R. B. Nussenblatt, Fortin, E., Schiffman, R., Rizzo, L., Smith, J., Van Veldhuisen, P., Sran, P., Yaffe, A., Goldman, C. K., Waldmann, T. A., and Whitcup, S. M., “Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: a phase I/II clinical trial.”, Proc Natl Acad Sci U S A, vol. 96, no. 13, pp. 7462-6, 1999.
2000
J. Copley, Staffeld, C., Lindberg, J., Bailey, C., and Van Veldhuisen, P., “Cyclosporine to tacrolimus: rejection, toxicity and cardiovascular risks”, 2000.
P. Martin, Crippin, J., Goldstein, R. M., Artinian, L., Van Veldhuisen, P., Klintmalm, G. D., and Busuttil, R. W., “Primary immunosuppressive agent does not affect Hepatitis C recurrence rates following liver transplantation”, 2000.
C. Johnson, Ahsan, N., Gonwa, T., Halloran, P., Stegall, M., Hardy, M., Metzger, R., Shield, C., Rocher, L., Scandling, J., Sorensen, J., Mulloy, L., Light, J., Corwin, C., Danovitch, G., Wachs, M., Van Veldhuisen, P., Salm, K., Tolzman, D., and Fitzsimmons, W. E., “Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation.”, Transplantation, vol. 69, no. 5, pp. 834-41, 2000.
C. Johnson, Ahsan, N., Gonwa, T., Halloran, P., Stegall, M., Hardy, M., Metzger, R., Shield, III, C., Rocher, L., Scandling, J., Sorensen, J., Mulloy, L., Light, J., Corwin, C., Danovitch, G., Wachs, M., Van Veldhuisen, P., Salm, K., Tolzman, D., and Fitzsimmons, W. E., “Randomized trial of tacrolimus (PROGRAF™) in combination with azathioprine or mychophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation”, Transplantation, vol. 69, pp. 834-41, 2000.
T. A. Gonwa, Johnson, C., Ahsan, N., ,, Stegall, M., Hardy, M., Metzger, R., Shield, C., Rocher, L., Scandling, J., Sorensen, J., Mulloy, L., Light, J., Corwin, C., Danovitch, G., Wachs, M., Van Veldhuisen, P., Salm, K., Tolzman, D., Scotellaro, P., and Fitzsimmons, W., “Untitled”, 2000.
R. B. Nussenblatt, Fortin, E., Schiffman, R., Risso, L., Smith, J., Van Veldhuisen, P., Sran, P., Yaffe, A., Goldman, C. K., Waldmann, T. A., and Whitcup, S. M., “The use of monoclonal therapy in the treatment of intraocular inflammatory disease”, 2000.
2001
N. Ahsan, Johnson, C., Gonwa, T., Halloran, P., Stegall, M., Hardy, M., Metzger, R., Shield, C., Rocher, L., Scandling, J., Sorensen, J., Mulloy, L., Light, J., Corwin, C., Danovitch, G., Wachs, M., Van Veldhuisen, P., Salm, K., Tolzman, D., and Fitzsimmons, W., “Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years”, Transplantation, vol. 72, pp. 245-50, 2001.
M. D. Sorrentino, Charsha-May, D. E., Angert, A., Meissner, C., Pauly, T., L Pena, P., Prober, C., Rodriguez, W., Rodriguez-Santa, J., Sanchez, P., Simoes, E., and Van Veldhuisen, P., “Severity of RSV LRI hospitalizations in 33 to 35 week and 36 week gestational age infants”, 2001.
I. Hand, Boron, M., and Van Veldhuisen, P., “Synagisâ (Palivizumab) prophylaxis of respiratory syncytial virus (RSV) infection - patient demographics and preliminary results from the 2000-2001 SynagisÒ Outcomes Registry”, 2001.
2002
W. Fitzsimmons, Thompson, D., Hariharan, S., and Van Veldhuisen, P., “Serum Creatinine as a Surrogate Endpoint for Graft Loss in Kidney Transplantation Validation Efforts from Multicenter Trials”, 2002.
2003
S. Cohen, Boron, M., Cohen, A., Van Veldhuisen, P., and Registry, T. Palivizuma, “Group patterns of RSV disease prophylaxis in infants with congenital heart disease (CHD): preliminary results from the 2002-2003 Palivizumab Outcomes Registry”, 2003.
M. Hudak, Boron, M., Cohen, A., Van Veldhuisen, P., and Group, thePalivizuma, “Palivizumab prophylaxis of RSV disease: demographic and risk factors results from the 2002-2003 Outcomes Registry”, 2003.
S. Cohen, Boron, M., Cohen, A., Van Veldhuisen, P., and Group, thePalivizuma, “Patterns of RSV Disease Prophylaxis in Infants with Congenital Heart Disease (CHD): Preliminary Results From the 2002-2003 Palivizumab Outcomes Registry”, J Perinatology, vol. 23, p. 594, 2003.
T. Gonwa, Johnson, C., Ahsan, N., Alfrey, E. J., Halloran, P., Stegall, M., Hardy, M., Metzger, R., C III, S., Rocher, L., Scandling, J., Sorensen, J., Mulloy, L., Light, J., Corwin, C., Danovitch, G., Wachs, M., Van Veldhuisen, P., Leonhardt, M., and Fitzsimmons, W. E., “Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years”, Transplantation, vol. 75, pp. 2048-53, 2003.
A. K. Freeman, Linowski, G. C., Brady, C., Lind, L., Van Veldhuisen, P., Singer, G., and Lebwohl, M., “Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas”, J Amer Acad Dermatology, vol. 48, pp. 564-8, 2003.
2004
J. Kim, Dally, L., Ederer, F., Gaasterland, D., Van Veldhuisen, P., Blackwell, B., Sullivan, E., Prum, B., Shafranov, G., Beck, A., Spaeth, G., and Investigators, A. G. I. S., “The Advanced Glaucoma Intervention Study (AGIS): 14. Distinguishing Progression of Glaucoma from Visual Field Fluctuations”, Ophthalmology, vol. 111, pp. 2109-2116, 2004.
A. Krupnick, Serle, J., Van Veldhuisen, P., Lind, L., Clarke, J., Singer, G., and Lebwohl, M., “Tacrolimus ointment for the treatment of eyelid dermatitis”, Cutis, vol. 73, pp. 267-71, 2004.
2005
E. Maloney, Yamano, Y., Van Veldhuisen, P., Sawada, T., Kim, N., Cranston, B., Hanchard, B., Jacobsen, S., and Hisada, M., “Follow-up Study of HTLV-I Viral Markers in Children in Jamaica”, in The 12th International Conference on Human Retrovirology: HTLV and Related Viruses, Montego Bay, Jamaica, 2005.
E. Woodle, Van Veldhuisen, P., and , “A Prospective, Randomized, Multicenter, Double-Blind Study of Early Corticosteroid Cessation Versus Long-Term Maintenance of Corticosteroid Therapy with Tacrolimus and Mycophenolate Mofetil in Primary Renal Transplant Recipients: One Year Report”, Transplant Proc, vol. 37, pp. 804-808, 2005.